Literature DB >> 8642865

Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia.

F Tajima1, T Kawatani, A Endo, H Kawasaki.   

Abstract

We studied the natural killer (NK) cell activity and in vitro production of the cytokines which can enhance NK activity (interleukin-1 beta (IL-1 beta), interferon gamma (IFN gamma), and interleukin-2 (IL-2)) after stimulation in 44 patients with acute leukemia (AL) and 14 normal controls. We also studied the influence of these parameters on relapse and the relapse-free survival (RFS) (after the date of assay) of the AL patients. The NK activity and the production of cytokines in the peripheral blood mononuclear cells (PBMNC) from 16 patients at the untreated or relapsed stage as well as from 12 patients after consolidation were significantly lower than those from controls (both P<0.01), and those from the 16 patients at maintenance or off treatment were also significantly lower than those from the controls (P<0.01 or P<0.05). RFS after the date of assay of the patients in remission with NK activity above the median value was significantly longer than that of the patients below the median (P<0.05). The production of cytokines in the PBMNC from patients who showed continuous complete remission for at least 6 months was higher than that from the patients who relapsed early. These findings suggest that impaired NK cell function and cytokine production are associated with early relapse of AL regardless of remission status.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8642865

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  34 in total

1.  Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia.

Authors:  Marc Buyse; Pierre Squifflet; Beverly J Lange; Todd A Alonzo; Richard A Larson; Jonathan E Kolitz; Stephen L George; Clara D Bloomfield; Sylvie Castaigne; Sylvie Chevret; Didier Blaise; Dominique Maraninchi; Kathryn J Lucchesi; Tomasz Burzykowski
Journal:  Blood       Date:  2011-04-25       Impact factor: 22.113

2.  IL-12, IL-15, and IL-18 pre-activated NK cells target resistant T cell acute lymphoblastic leukemia and delay leukemia development in vivo.

Authors:  Margherita Boieri; Aina Ulvmoen; Amanda Sudworth; Clare Lendrem; Matthew Collin; Anne M Dickinson; Lise Kveberg; Marit Inngjerdingen
Journal:  Oncoimmunology       Date:  2017-01-17       Impact factor: 8.110

Review 3.  NK cells: key to success of DC-based cancer vaccines?

Authors:  Eva Lion; Evelien L J M Smits; Zwi N Berneman; Viggo F I Van Tendeloo
Journal:  Oncologist       Date:  2012-08-20

4.  The natural product phyllanthusmin C enhances IFN-γ production by human NK cells through upregulation of TLR-mediated NF-κB signaling.

Authors:  Youcai Deng; Jianhong Chu; Yulin Ren; Zhijin Fan; Xiaotian Ji; Bethany Mundy-Bosse; Shunzong Yuan; Tiffany Hughes; Jianying Zhang; Baljash Cheema; Andrew T Camardo; Yong Xia; Lai-Chu Wu; Li-Shu Wang; Xiaoming He; A Douglas Kinghorn; Xiaohui Li; Michael A Caligiuri; Jianhua Yu
Journal:  J Immunol       Date:  2014-08-13       Impact factor: 5.422

5.  The future of cellular immunotherapy for childhood leukemia.

Authors:  Challice L Bonifant; Sarah K Tasian
Journal:  Curr Opin Pediatr       Date:  2020-02       Impact factor: 2.856

6.  Differential response to cytotoxic therapy explains treatment dynamics of acute myeloid leukaemia patients: insights from a mathematical modelling approach.

Authors:  H Hoffmann; C Thiede; I Glauche; M Bornhaeuser; I Roeder
Journal:  J R Soc Interface       Date:  2020-09-09       Impact factor: 4.118

7.  MicroRNA-29b mediates altered innate immune development in acute leukemia.

Authors:  Bethany L Mundy-Bosse; Steven D Scoville; Li Chen; Kathleen McConnell; Hsiaoyin C Mao; Elshafa H Ahmed; Nicholas Zorko; Sophia Harvey; Jordan Cole; Xiaoli Zhang; Stefan Costinean; Carlo M Croce; Karilyn Larkin; John C Byrd; Sumithira Vasu; William Blum; Jianhua Yu; Aharon G Freud; Michael A Caligiuri
Journal:  J Clin Invest       Date:  2016-10-24       Impact factor: 14.808

8.  Generation and preclinical characterization of a Fc-optimized GITR-Ig fusion protein for induction of NK cell reactivity against leukemia.

Authors:  Benjamin Joachim Schmiedel; Antje Werner; Julia Steinbacher; Tina Nuebling; Corina Buechele; Ludger Grosse-Hovest; Helmut Rainer Salih
Journal:  Mol Ther       Date:  2013-02-05       Impact factor: 11.454

9.  Activation of the Intracellular Pattern Recognition Receptor NOD2 Promotes Acute Myeloid Leukemia (AML) Cell Apoptosis and Provides a Survival Advantage in an Animal Model of AML.

Authors:  Nathaniel J Buteyn; Ramasamy Santhanam; Giovanna Merchand-Reyes; Rakesh A Murugesan; Gino M Dettorre; John C Byrd; Anasuya Sarkar; Sumithira Vasu; Bethany L Mundy-Bosse; Jonathan P Butchar; Susheela Tridandapani
Journal:  J Immunol       Date:  2020-02-24       Impact factor: 5.422

10.  Use of natural killer cells as immunotherapy for leukaemia.

Authors:  Bartosz Grzywacz; Jeffrey S Miller; Michael R Verneris
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.